Main menu

Genomic analysis of germline and somatic lesions at the FCGR locus; from reference genomes to clinicobiological implications


Monoclonal antibody (mAb) immunotherapy is becoming standard in the treatment of cancer, particularly for B-cell lymphoma patients. However responses are variable and relapse is common, thus the molecular mechanisms that underpin resistance need to be defined. mAbs interact with the Fc gamma receptors (FcγRs), a family of cell surface molecules crucial in the immune response. Human cells express six FcγRs: the high-affinity FcγRI and 5 low-affinity receptors which have both activatory (FcγRIIa, FcγRIIc, FcγRIIIa and FcγRIIIb) and inhibitory (FcγRIIb) capabilities.

Download the PDF

入門

MinION Starter Packを購入 ナノポア製品の販売 シークエンスサービスプロバイダー グローバルディストリビューター

お問い合わせ

Intellectual property Cookie policy Corporate reporting Privacy policy Terms & conditions Accessibility

Oxford Nanoporeについて

Contact us 経営陣 メディアリソース & お問い合わせ先 投資家向け Oxford Nanopore社で働く BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Japanese flag